Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: Real-world insights

European Respiratory Journal

Volumn 46, Issue 2, 2015, Pages 414-421

  Dardi, Fabio ^a   Manes, Alessandra ^a   Palazzini, Massimiliano ^a   Bachetti, Cristina ^a   Mazzanti, Gaia ^a   Rinaldi, Andrea ^a   Albini, Alessandra ^a   Gotti, Enrico ^a   Monti, Enrico ^a   Reggiani, Maria Letizia Bacchi ^a   Galiè, Nazzareno ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; SILDENAFIL; ANTIHYPERTENSIVE AGENT; SULFONAMIDE; VASODILATOR AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GENETIC DISORDER; HEART RIGHT ATRIUM PRESSURE; HOSPITALIZATION FREE SURVIVAL; HUMAN; HYPERTRANSAMINASEMIA; IDIOPATHIC DISEASE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; OVERALL SURVIVAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; TRIPLE COMBINATION THERAPY FREE SURVIVAL; CAUSE OF DEATH; COMBINATION DRUG THERAPY; COMPLICATION; CONGENITAL HEART MALFORMATION; DRUG EFFECTS; EXERCISE TEST; HEMODYNAMICS; HYPERTENSION, PULMONARY; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CAUSE OF DEATH; CHILD; CONNECTIVE TISSUE DISEASES; DRUG THERAPY, COMBINATION; EXERCISE TEST; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; HEART DEFECTS, CONGENITAL; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SILDENAFIL CITRATE; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84938871208     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00209914     Document Type: Article

References (20)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
2. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; 30: 2493-2537.
3. Sitbon O, Simonneau G. Optimal management of severe pulmonary arterial hypertension. Eur Respir Rev 2011; 20: 254-261.
4. Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010; 31: 2080-2086.
5. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: Suppl., D60-D72.
6. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.
7. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-340.
8. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818.
9. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186: 790-796.
10. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168: 871-880.
11. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
12. Humbert M, Sitbon O, Yaci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
13. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
14. Bai Y, Sun L, Hu S, et al. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology 2011; 120: 157-165.
15. Manes A, Palazzini M, Tremblay G, et al. Combination therapy for pulmonary arterial hypertension (PAH) reduces consistently clinical worsening as compared to monotherapy: an updated meta-analysis of randomized controlled trials. Eur Heart J 2014; 35: Suppl. 1, 68.
16. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
17. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448-456.
18. Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2014; 35: 716-724.
19. Gruenig E, Michelakis E, Vachiéry J-L, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol 2009; 49: 1343-1352.
20. Burgess G, Hoogkamer H, Collings L, et al. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008; 64: 43-50.